Claims

1. A pharmaceutical composition comprising a *Cannabis* extract and optionally one or more pharmaceutically acceptable carriers, diluents, adjuvants, excipients or any combination thereof, the *Cannabis* extract comprising a cannabinoid fraction and a terpene fraction, wherein the *Cannabis* extract comprises either:

A:

- ≥ 0.3% w/w of the terpene fraction;
- ≥ 50% w/w Δ^9-Tetrahydrocannabinol (THC);
- ≥ 0.3% w/w Cannabigerol (CBG); and
- ≤ 0.5% w/w Cannabinodiol (CBN).

or

B:

- ≥ 0.5% w/w of the terpene fraction;
- ≥ 60% w/w CBD;
- ≤ 3% w/w THC; and
- ≤ 0.1% w/w CBN;

wherein the terpene fraction comprises:

- ß-caryophyllene in an amount of at least 11% by weight of the terpene fraction, and

one or more of:

- linalool in an amount of at least 5% by weight of the terpene fraction; and
- ß-pinene in an amount of at least 1% by weight of the terpene fraction.

2. The pharmaceutical composition according to claim 1, wherein the *Cannabis* extract is a *Cannabis* oil.

3. The pharmaceutical composition according to claim 1 or 2, wherein the *Cannabis* extract comprises Δ^9-tetrahydrocannabinol (THC) in an amount of from 50% to 99% by weight of the pharmaceutical composition.

4. The pharmaceutical composition according to claim 1 or 2, comprising cannabidiol (CBD) in an amount of from 60% to 99% by weight of the pharmaceutical composition.

5. The pharmaceutical composition according to any one of claims 1 to 4, wherein the

Cannabis extract comprises one or more additional cannabinoids selected from Δ^9-Tetrahydrocannabinolic acid (THCA), Δ^9-Tetrahydrocannabivarin (THCV), and (-)-Cannabidivarin (CBDV).

6. The pharmaceutical composition according to any one of claims 1 to 5, wherein the terpene fraction comprises both linalool and ß-pinene.

7. The pharmaceutical composition according to any one of claims 1 to 6, wherein the terpene fraction further comprises one or more of ß-myrcene, D-limonene, a nerolidol and α-pinene..

8. The pharmaceutical composition according to any one of claims 1 to 7, wherein the terpene fraction further comprises one or more of α-bisabolol, caryophyllene oxide, p-cymene, isopulegol, ocimene, α-terpinene, γ-terpinene, δ-s-carene, guaiol, and terpinolene.

9. The pharmaceutical composition according to any one of claims 1 to 8, wherein the pharmaceutically acceptable carrier is sesame oil.

10. The pharmaceutical composition according to any one of claims 1 to 9, further comprising an active agent other than the *Cannabis* extract.

11. Use of a *Cannabis* extract in the preparation of a medicament for treating cancer or a symptom associated with cancer, wherein the *Cannabis* extract comprises a cannabinoid fraction and a terpene fraction, and wherein the *Cannabis* extract comprises either:

A:

- ≥ 0.3% w/w of the terpene fraction;
- ≥ 50% w/w Δ^9-Tetrahydrocannabinol (THC);
- ≥ 0.3% w/w Cannabigerol (CBG); and
- ≤ 0.5% w/w Cannabinodiol (CBN).

or

B:

- ≥ 0.5% w/w of the terpene fraction;
- ≥ 60% w/w CBD;
- ≤ 3% w/w THC; and
- ≤ 0.1% w/w CBN.

12. The use of claim 11, wherein the terpene fraction comprises:

- ß-caryophyllene in an amount of at least 11% by weight of the terpene fraction, and

one or more of:

- linalool in an amount of at least 5% by weight of the terpene fraction; and
- ß-pinene in an amount of at least 1% by weight of the terpene fraction.

13. The use according to claim 11 or claim 12, wherein the cancer is breast cancer.

14. The use according to claim 13, wherein the breast cancer is selected from HER2 positive, triple negative and hormone receptor positive breast cancer.

15. The pharmaceutical composition according to any one of claims 1 to 10 for use in treating cancer or a symptom associated with cancer.

16. The pharmaceutical composition for use according to claim 15, wherein the cancer is breast cancer.

17. The pharmaceutical composition for use according to claim 16, wherein the breast cancer is selected from HER2 positive, triple negative and hormone receptor positive breast cancer.